- Home
- TIL
TIL
Instil Bio Inc.
as 09-18-2025 4:00pm EST
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 177.1M | IPO Year: | 2021 |
| Target Price: | $120.50 | AVG Volume (30 days): | 150.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.80 - $73.69 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Instil Bio Inc. (TIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Laumas Sandeep | TIL | CFO and CBO | Sep 10 '25 | Sell | $23.46 | 30,000 | $701,667.24 | 12,461 |
Latest Instil Bio Inc. News
TIL Breaking Stock News: Dive into TIL Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
Zacks
3 months ago
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Zacks
3 months ago
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
GlobeNewswire
3 months ago
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Zacks
3 months ago
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
GlobeNewswire
4 months ago
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
4 months ago
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Zacks
4 months ago
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Compare TIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TIL Instil Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.